NCT05160922Active, not recruitingPhase 4
Crizotinib Continuation Clinical Study
CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 6 Dec 2021
- Start date
- 27 Dec 2021
- Primary completion date
- 21 Mar 2028
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT05160922
- EU CT number
- 2024-511128-15-00
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 27
- From 27 Dec 2021 to the primary completion date, 21 Mar 2028
- 13 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with any of the following characteristics/conditions will be excluded:
Other
- Female participants who are pregnant or breastfeeding.
- Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
Criteria the registry did not label
- Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:
- Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close.
- Participants must agree to follow the reproductive criteria as outlined in protocol.
- No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4.
- Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.
- Pediatric Participants (\<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Science Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Jilin Cancer Hospital Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
| Fujian Province Oncology Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| The First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| The First Affiliated Hospital of College of Medicine,Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Wuhou District | China | Unknown status |
| ASST Monza Coordinator of this site? Confirm its status | Monza | Italy | Unknown status |
| National Hospital Organization Nagoya Medical Center Coordinator of this site? Confirm its status | Nagoya | Japan | Unknown status |
| Limited Liability Company "EuroCityClinic" Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Unknown status |
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.